Birth Control in Clinical Trials: Industry Survey of Current Use Practices, Governance, and Monitoring

Therapeutic Innovation and Regulatory Science

Volumn 50, Issue 2, 2016, Pages 155-168

  Stewart, J ^a   Breslin, W J ^b   Beyer, B K ^c   Chadwick, K ^d   De Schaepdrijver, L ^e   Desai, M ^f   Enright, B ^f   Foster, W ^g   Hui, J Y ^h   Moffat, G J ⁱ   Tornesi, B ^f   Van Malderen, K ^j   Wiesner, L ^k   Chen, C L ^l  

^a ASTRAZENECA   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c SANOFI   (France)

^d BRISTOL MYERS SQUIBB   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f ABBVIE INC   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h CELGENE CORPORATION   (United States)

ⁱ AMGEN INC   (United States)

^j Federal Agency for Medicines and Health Products Belgium   (Belgium)

^k FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^l ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

more..

Author keywords

clinical trials; contraception; industry approaches; informed consent

Indexed keywords

ARTICLE; BIRTH CONTROL; CONTRACEPTION; DRUG INDUSTRY; HEALTH CARE QUALITY; HUMAN; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 84959175944     PISSN: 21684790     EISSN: 21684804     Source Type: Journal    
DOI: 10.1177/2168479015608415     Document Type: Article

References (19)

1. ICH. ICH Harmonized Tripartite Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials for the Conduct of Human Trials and Marketing Authorization for Pharmaceuticals M3(R2). 2009.
2. UK MHRA. Clarification of contraceptive wording in clinical trials (version 2, amended 21 May 2010). 2010.
3. E.W.NgP.ChiruvoluG.F.LevyB.R.AllanD.F.Wyszynski. Contraception language in informed consent forms: a survey of biopharmaceutical companies. Drug Inform J. 2012;46:329–335.
4. UK MHRA. Recommendations related to contraception and pregnancy testing in clinical trials. Advisory non-binding guidance supported by national competent authorities represented at the CTFG-meeting in Rome 2014-09-15. 2014.
5. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. Geneva: Department of Reproductive Health, WHO; 2010.
6. C.L.ChenB.K.BeyerW.J.Breslin. Introduction to the HESI DART Drugs in Semen Consortium. Reprod Toxicol. 2014;48:113–114.
7. J.Y.HuiM.HoffmannG.Kumar. Embryo-fetal exposure and developmental outcome of thalidomide following oral and intravaginal administration to pregnant rabbits. Reprod Toxicol. 2014;48:115–123.
8. W.J.BreslinK.G.HilbishT.J.PageD.E.Coutant. Assessment of fetal exposure risk following seminal excretion of a therapeutic IgG4 (T-IgG4) monoclonal antibody using a rabbit model. Reprod Toxicol. 2014;48:124–131.
9. G.J.MoffatR.DaviesG.Kwon. Investigation of maternal and fetal exposure to an IgG2 monoclonal antibody following biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy. Reprod Toxicol. 2014;48:132–137.
10. J.CaoX.YingB.K.BeyerA.M.DeLise. The use of optical imaging to assess the potential for embryo-fetal exposure to an exogenous material after intravaginal administration. Reprod Toxicol. 2014;48:138–147.
11. C.WesthoffA.Davis. Tubal sterilization: focus on the U.S. experience. Fertil Steril. 2000;73:913–922.
12. ICH. ICH Harmonized Tripartite Guideline: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1). 2011.
13. M.SilvermanA.ShefferP.V.Diaz. Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide. Ann Allergy Asthma Immunol. 2005;95:566–570.
14. ACOG Committee Opinion No. 577: Understanding and using the U.S. selected practice recommendations for contraceptive use, 2013. Obstet Gynecol. 2013;122:1132–1133.
15. L.KlemmtA.R.Scialli. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol. 2005;74:119–131.
16. M.L.BanholzerH.BuerginC.Wandel. Clinical trial considerations on male contraception and collection of pregnancy information from female partners. J Transl Med. 2012;10:129.
17. L.B.FinerS.K.Henshaw. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38:90–96.
18. National Institute for Health Care and Excellence. Long-acting reversible contraception (update). NICE Clinical Guidline 30 (Issued October 2005). London: NICE; 2014.
19. C.ParottiE.W.NgD.F.Wyszynski. Contraception methods in drug labeling. Drug Inform J. 2012;46:320–328.